Metastatic cutaneous apocrine adenocarcinoma successfully treated with systemic anti-androgen therapy-A case report

Fanny Collette; Marc Hamoir; Pascal Van Eeckhout; Philippe D'Abadie; Thierry Duprez; Sandra Schmitz; Jean-Pascal Machiels

doi:10.1002/ccr3.3434

Metastatic cutaneous apocrine adenocarcinoma successfully treated with systemic anti-androgen therapy-A case report

Clin Case Rep. 2020 Oct 30;8(12):3472-3478. doi: 10.1002/ccr3.3434. eCollection 2020 Dec.

Authors

Fanny Collette¹, Marc Hamoir², Pascal Van Eeckhout³, Philippe D'Abadie⁴, Thierry Duprez⁵, Sandra Schmitz², Jean-Pascal Machiels¹

Affiliations

¹ Institut Roi Albert II Department of Medical Oncology Cliniques universitaires Saint-Luc and Institut de Recherche Clinique et Expérimentale (POLE MIRO) Université catholique de Louvain Brussels Belgium.
² Institut Roi Albert II Department of Head and Neck Surgery Cliniques universitaires Saint-Luc and Institut de Recherche Clinique et Expérimentale (POLE MIRO) Université catholique de Louvain Brussels Belgium.
³ Institut Roi Albert II Department of Pathology Cliniques universitaires Saint-Luc Brussels Belgium.
⁴ Institut Roi Albert II Department of Nuclear Medicine Cliniques universitaires Saint-Luc and Institut de Recherche Clinique et Expérimentale (POLE MIRO) Université catholique de Louvain Brussels Belgium.
⁵ Institut Roi Albert II Department of Medical Imaging Cliniques universitaires Saint-Luc Brussels Belgium.

Abstract

Primary cutaneous apocrine adenocarcinoma (PCAC) is an extremely rare neoplasm involving the sweat glands. Due to a lack of cases, there is no consensus for the systemic treatment of locally advanced or metastatic PCAC. Anti-androgen therapy may have activity in inoperable or metastatic PCAC with high androgen receptor (AR) expression.

Keywords: Primary cutaneous apocrine adenocarcinoma; androgen receptor; anti‐androgen therapy; metastatic cancer; sweat glands.

Publication types

Case Reports